# Patient-Trial Match Report

*Generated: 2026-01-05 06:54:30*

## Patient Profile

- **Age**: 65
- **Sex**: Male
- **Cancer Type**: NSCLC
- **Biomarkers**: KRAS G12C

**Clinical Description**:
> 65-year-old male diagnosed with Stage IV non-small cell lung cancer (adenocarcinoma) in March 2024. KRAS G12C mutation confirmed by NGS (FoundationOne CDx). Initial treatment with carboplatin/pemetrexed + pembrolizumab x6 cycles achieved partial response. Progressive disease noted on surveillance CT in November 2025 with new hepatic metastases. Currently asymptomatic with mild dyspnea on exertion. No history of autoimmune disease. Former smoker (30 pack-years, quit 2019). Creatinine 1.1, LFTs normal, ANC 3.2, platelets 245k.

- **Location Preference**: United States

## Search Summary

- **Search terms used**: 12
- **Total trials evaluated**: 100
- **Excluded by fast filter**: 15
- **LLM scored**: 85

## ðŸŸ¢ HIGH Likelihood (26 trials)

### [NCT05853575](https://clinicaltrials.gov/study/NCT05853575)

**A Randomized Study of Two Dosing Regimens of Adagrasib in Patients With Previously Treated Non-Small Cell Lung Cancer With KRAS G12C Mutation**

- **Sponsor**: Mirati Therapeutics Inc.
- **Phase**: Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Age: 65
- Sex: male
- Cancer type: NSCLC
- Biomarkers: KRAS G12C
- ECOG status: 1
- Prior therapies: carboplatin/pemetrexed, pembrolizumab
- Brain metastases: none

**? Uncertainties:**
- Blood test results: creatinine, LFTs, ANC, platelets are provided but categorization of recovery from prior treatment is unclear.

**Assessment:**
> The patient's cancer type is NSCLC and includes the required KRAS G12C mutation. The patient has received prior treatment with carboplatin and an immune checkpoint inhibitor. There are no ongoing brain metastases or concerning blood test results, suggesting likely recovery from prior therapies.

---

### [NCT06162221](https://clinicaltrials.gov/study/NCT06162221)

**A Platform Study of RAS(ON) Inhibitors in Patients With RAS-Mutated Non-Small Cell Lung Cancer (NSCLC)**

- **Sponsor**: Revolution Medicines, Inc.
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Age: 65
- ECOG status: 1
- Cancer type: NSCLC
- Biomarkers: KRAS G12C
- Prior therapies: carboplatin/pemetrexed, pembrolizumab
- No brain metastases

**? Uncertainties:**
- Organ function (Creatinine, LFTs are normal but not explicitly outlined if considered adequate by study)
- Study specific adequacy of organ function not confirmed

**Assessment:**
> The patient has NSCLC (which matches the trial's focus) and is KRAS G12C-mutated, fulfilling the biomarker requirement. The ECOG status and age meet the eligibility requirements. The history of treatment does not contradict the inclusion criteria. However, organ function adequacy is not explicitly confirmed, warranting some uncertainty.

---

### [NCT06881784](https://clinicaltrials.gov/study/NCT06881784)

**RASolve 301: Phase 3 Multicenter, Open Label, Randomized Study of RMC-6236 Versus Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic RAS[MUT] NSCLC**

- **Sponsor**: Revolution Medicines, Inc.
- **Phase**: Phase 3
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Age is 65 (acceptable age for trial)
- ECOG status is 1
- Cancer type is NSCLC (pathologically confirmed)
- Has measurable disease per RECIST v1.1
- Adequate organ function: creatinine 1.1, LFTs normal, ANC 3.2, platelets 245k
- Has documented RAS mutation status (KRAS G12C)
- Patient has had one prior line of therapy including an anti-PD-1 agent (pembrolizumab) and platinum-based chemotherapy (carboplatin/pemetrexed)

**âœ— Potential Conflicts:**
- Patient has prior therapy with pembrolizumab which is an anti-PD-1 agent, hence can't receive docetaxel or direct RAS-targeted therapy.

**Assessment:**
> The patient meets the disease type and treatment line criteria for the trial, as they have NSCLC and have received acceptable prior treatments. All eligibility criteria are met, leading to a high likelihood of eligibility.

---

### [NCT02178163](https://clinicaltrials.gov/study/NCT02178163)

**A Study to Assess the Ability to Initiate Therapy in Advanced Non-small Cell Lung Cancer (NSCLC) Patients Based on Genomic Analyses of Tumor Specimens.**

- **Sponsor**: Barbara Ann Karmanos Cancer Institute
- **Phase**: Not Applicable
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has Stage IV non-small cell lung cancer (adenocarcinoma).
- ECOG status is 1.
- Absolute neutrophil count is 3.2, which is above 1.5 x 10^9/L.
- Platelet count is 245k, which is above 100,000 x 10^9/L.
- Serum creatinine is 1.1, within the acceptable range.
- No brain metastases.

**? Uncertainties:**
- Serum bilirubin levels are not provided, so their status relative to ULN is unknown.
- Transaminase levels are not provided, so we cannot confirm if they meet the criteria.

**Assessment:**
> The patient's cancer type matches the trial's indication for advanced NSCLC. He has prior treatment, which aligns with the inclusion of previously treated patients in the trial. His ECOG status and organ function parameters are within acceptable ranges, though certain laboratory values are unspecified.

---

### [NCT05005403](https://clinicaltrials.gov/study/NCT05005403)

**A Global First-in-Human Study in NSCLC, HNSCC and Solid Tumors With Azirkitug (ABBV-514) as a Single Agent and in Combination With Budigalimab or Bevacizumab**

- **Sponsor**: AbbVie
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has NSCLC (non-small cell lung cancer) which is a target indication of the trial.
- Patient has an ECOG performance status of 1.
- Patient has previously received standard of care therapy (carboplatin/pemetrexed and pembrolizumab) and has progressive disease.
- Patient has a documented KRAS G12C mutation.

**Assessment:**
> The patient's cancer type (NSCLC) matches the trial's target indication. The patient is previously treated, having progressed after standard therapies, which aligns with the trial's criteria for previously treated patients. There are no conflicts or uncertainties regarding the patient's eligibility for this trial.

---

### [NCT05815173](https://clinicaltrials.gov/study/NCT05815173)

**Phase I/II Study of Ladarixin and Sotorasib in Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer (NSCLC)**

- **Sponsor**: NYU Langone Health
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Age: 65
- Sex: male
- Cancer type: NSCLC
- Biomarker: KRAS G12C mutation confirmed
- ECOG status: 1
- Progressive disease following treatment with anti-PD(L)-1 with chemotherapy
- No brain metastases

**? Uncertainties:**
- No specific organ function lab results are provided.
- Documentation of the presence of the KRAS G12C mutation is confirmed by NGS, satisfying the need for documentation.

**Assessment:**
> The patient's cancer type matches the study's indication, as they have confirmed KRAS G12C mutant NSCLC. They have also demonstrated progression of disease after prior therapy, matching the treatment line criteria. All supporting factors indicate eligibility.

---

### [NCT06343402](https://clinicaltrials.gov/study/NCT06343402)

**A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-8520 in Subjects With Advanced KRASG12C Mutant Non-Small Cell Lung Cancer - The ONKORAS-101 Study**

- **Sponsor**: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Histologically documented advanced stage IV non-small cell lung cancer with KRAS G12C mutation
- ECOG performance status of 1

**Assessment:**
> The patient's cancer type (NSCLC, KRAS G12C), prior treatment with pembrolizumab, and ECOG status all align with the trial's inclusion criteria. Additionally, the patient has no untreated brain metastases, maintaining trial eligibility.

---

### [NCT05410145](https://clinicaltrials.gov/study/NCT05410145)

**A Phase 1/2, Open Label, Dose-escalation, and Dose-expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation**

- **Sponsor**: D3 Bio (Wuxi) Co., Ltd
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has a confirmed diagnosis of metastatic NSCLC.
- Patient has documented KRAS G12C mutation identified within the last 5 years.
- Patient has an ECOG performance status of 1.
- Patient has adequate organ and marrow function.
- Patient has measurable disease as evidenced by progressive disease noted on surveillance CT.

**Assessment:**
> The patient's cancer type is NSCLC, which aligns with the trial's focus on KRAS p.G12C mutations. The patient has previously received treatment but this trial allows previously treated patients, and all other criteria are met, leading to strong confidence in eligibility.

---

### [NCT05786924](https://clinicaltrials.gov/study/NCT05786924)

**A Phase 1/2, Open-label Study of Oral S241656 (BDTX-4933) as Monotherapy and in Combination With Other Anti-Cancer Therapies in Patients With KRAS, BRAF and Other Selected RAS/MAPK Mutation-Positive Malignancies**

- **Sponsor**: Institut de Recherches Internationales Servier
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has Stage IV NSCLC which matches the study condition of non-small cell lung cancer.
- Patient has a confirmed KRAS G12C mutation as required by the trial.
- Patient's ECOG status is 1, indicating acceptable performance status.
- Patient does not have brain metastases.

**Assessment:**
> The patient has a confirmed diagnosis of Stage IV NSCLC and possesses the KRAS G12C mutation, which aligns with the trial's eligibility criteria. The patient's treatment history also suggests they can fit into the treatment line required for the trial.

---

### [NCT06244771](https://clinicaltrials.gov/study/NCT06244771)

**An Open-Label, Phase 1/2 Dose Escalation, Dose Expansion and Cohort Expansion Study Evaluating the Safety, PK and Clinical Activity of FMC-376 in Participants With KRAS G12C Mutated Locally Advanced Unresectable or Metastatic Solid Tumors**

- **Sponsor**: Frontier Medicines Corporation
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has NSCLC with KRAS G12C mutation
- ECOG status is 1
- Patient has adequate hematological function
- No brain metastases

**âœ— Potential Conflicts:**
- None

**? Uncertainties:**
- Renal and hepatic function specifics are not provided

**Assessment:**
> The patient's cancer type (NSCLC with KRAS G12C mutation) matches the trial's inclusion criteria. The patient is previously treated, which aligns with the trial's requirement for previously treated patients with progression on standard therapies. The ECOG performance status is acceptable, and no brain metastases are present, although details on renal and hepatic function are unspecified.

---

### [NCT06814496](https://clinicaltrials.gov/study/NCT06814496)

**RAdiation comBined With BIspecific T-Cell Engager in DLL3 Expressing Tumors (RABBIT) Study: A Phase I/II Study of AMG757 / Tarlatamab and Concurrent Radiation Therapy in Tumors With High Prevalence of DLL3**

- **Sponsor**: University of Arizona
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has NSCLC, which is included in the trial conditions.
- Patient is 65 years old, which is over 18 years of age.
- ECOG status is 1, which is within the acceptable range (0-2).
- Patient has prior therapy (pembrolizumab) and meets the inclusion requirement of having progressed after at least one line of therapy.
- Patient has a minimum life expectancy of more than 12 weeks.
- Patient is asymptomatic with mild dyspnea on exertion, which does not qualify as substantial symptoms.
- Patient has no history of autoimmune disease.

**? Uncertainties:**
- Need verification on whether the patient's lesion is measurable as defined by RECIST 1.1.
- Confirmation on whether the patient is eligible for external beam radiation therapy to a previously unirradiated measurable lesion.

**Assessment:**
> The patient's cancer type (NSCLC) matches the conditions studied in the trial. They also meet the age, ECOG performance status, treatment line requirements, and have no contraindicating medical history. Remaining uncertainties concern specific eligibility details related to measurable lesions and radiation therapy eligibility.

---

### [NCT06973564](https://clinicaltrials.gov/study/NCT06973564)

**A Phase 1/2a, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of JAB-23E73 in Adult Patients With Advanced Solid Tumors With KRAS Alteration**

- **Sponsor**: Jacobio Pharmaceuticals Co., Ltd.
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Age: 65
- Sex: male
- Cancer type: NSCLC
- Biomarkers: KRAS G12C
- ECOG status: 1
- Prior therapies: carboplatin/pemetrexed, pembrolizumab
- No brain metastases
- Life expectancy â‰¥3 months
- Has at least one measurable lesion (hepatic metastases)

**Assessment:**
> The patient's cancer type (NSCLC) matches the study indication, and they have the required KRAS alteration (G12C). The patient is >18 years old, has a suitable ECOG status, and prior therapies align with criteria for previously treated patients, indicating they likely qualify for the trial.

---

### [NCT00068003](https://clinicaltrials.gov/study/NCT00068003)

**Cell Harvest and Preparation for Surgery Branch Treatment Protocols**

- **Sponsor**: National Cancer Institute (NCI)
- **Phase**: N/A
- **Status**: Enrolling by invitation
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has NSCLC, which is included in the trial conditions studied.
- Patient has ECOG status of 1, which is acceptable for the trial.
- Patient is 65 years old, which meets the age criteria.
- Patient has no brain metastases.

**? Uncertainties:**
- HIV serology status is not provided.
- Hepatitis B and C serology status is not provided.

**Assessment:**
> The patient's NSCLC diagnosis aligns with the trial's eligibility criteria. The patient is ECOG status 1 and aged 65, which is acceptable. There are only minor uncertainties regarding serology status for HIV and hepatitis, but overall, the patient seems likely to qualify.

---

### [NCT05067283](https://clinicaltrials.gov/study/NCT05067283)

**A Phase 1, Open-label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and as Part of Various Combination Therapies in Participants With KRAS G12C Mutant Advanced Solid Tumors**

- **Sponsor**: Merck Sharp & Dohme LLC
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has NSCLC, which is the focus of the trial
- Patient has a confirmed KRAS G12C mutation
- Patient has received at least 1 line of therapy for systemic disease (carboplatin/pemetrexed and pembrolizumab)

**Assessment:**
> The patient's diagnosis of NSCLC with a KRAS G12C mutation aligns with the trial's focus. The patient is also previously treated, meeting the necessary treatment line criteria. There are no noted conflicts or uncertainties regarding the eligibility criteria provided.

---

### [NCT05076760](https://clinicaltrials.gov/study/NCT05076760)

**Phase I Study Evaluating MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors**

- **Sponsor**: Memgen, Inc.
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Cancer type is NSCLC, which is included in the trial conditions studied.
- ECOG status is 1, which meets the trial's eligibility criteria.
- Patient has progressed on prior therapy including pembrolizumab, satisfying the requirements for Part 1B or 1C.
- Age is 65, which is above the minimum age requirement of 18 years.
- Creatinine level (1.1) supports adequate organ function.
- ANC (3.2) and platelets (245k) meet the requirements for adequate organ and marrow function.

**Assessment:**
> The patient's NSCLC diagnosis matches the trial's indication; the patient is previously treated, which aligns with the requirements. The patient meets the ECOG and organ function criteria, with no significant conflicts or uncertainties noted.

---

### [NCT06026410](https://clinicaltrials.gov/study/NCT06026410)

**Phase 1, First-in-Human, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of KO-2806 When Administered as Monotherapy and in Combination Therapy in Adult Patients With Advanced Solid Tumors**

- **Sponsor**: Kura Oncology, Inc.
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Age: 65
- Sex: male
- Cancer type: NSCLC
- Biomarkers: KRAS G12C
- ECOG status: 1
- Prior therapies: carboplatin/pemetrexed, pembrolizumab
- Brain metastases: none

**? Uncertainties:**
- Creatinine level is provided but categorized as normal
- LFTs are normal but specific values are not provided
- ANC (3.2) and platelets (245k) are provided but lack reference ranges

**Assessment:**
> The patient's NSCLC diagnosis matches the trial's focus on advanced solid tumors, and the presence of the KRAS G12C mutation aligns with the inclusion criteria for NSCLC patients who have received prior systemic therapy. The patient has an ECOG status of 1 and is otherwise asymptomatic, indicating acceptable performance status and organ function. Although there are minor uncertainties in lab values, the overall profile supports eligibility.

---

### [NCT06128551](https://clinicaltrials.gov/study/NCT06128551)

**Phase 1b, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 in Combination with RMC-6236 in Participants with Advanced KRAS G12C Mutant Solid Tumors**

- **Sponsor**: Revolution Medicines, Inc.
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has NSCLC (non-small cell lung cancer)
- Patient has KRAS G12C mutation
- Patient has ECOG status of 1
- Patient has prior treatment history with chemotherapy and immunotherapy

**? Uncertainties:**
- Creatinine levels and general organ function are provided but not specifically stated in terms of trial eligibility
- Liver function test results are normal but not specified in detail

**Assessment:**
> The patient's cancer type matches exactly what the trial is studying (NSCLC with KRAS G12C mutation). The patient has also received prior therapies, which fits the trial's inclusion criteria for previously treated patients. While there are minor uncertainties regarding organ function tests, the main criteria for eligibility strongly indicate that the patient qualifies.

---

### [NCT06400472](https://clinicaltrials.gov/study/NCT06400472)

**A First-in-Human, Phase 1a/1b Trial to Assess the Safety, Tolerability and Preliminary Efficacy of LY4170156, an Antibody-Drug Conjugate Targeting Folate Receptor Î±-Expressing Tumor Cells, in Participants With Selected Advanced Solid Tumors**

- **Sponsor**: Eli Lilly and Company
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Diagnosis of non-small cell lung cancer (NSCLC)
- ECOG status of 1
- No brain metastases
- Prior treatment of carboplatin/pemetrexed and pembrolizumab

**Assessment:**
> The patient's cancer type of NSCLC matches the trial's conditions. The patient has been treated previously, but the trial appears open to previously treated patients, and there are no conflicts with inclusion or exclusion criteria. Thus, the patient likely qualifies.

---

### [NCT06403436](https://clinicaltrials.gov/study/NCT06403436)

**A Phase 1, First-in-Human, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors**

- **Sponsor**: TOLREMO therapeutics AG
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- ECOG status 1
- Age 65
- No brain metastases
- Creatinine 1.1
- LFTs normal
- ANC 3.2
- Platelets 245k
- Measurable disease per RECIST 1.1 criteria implied by progressive disease after treatment

**? Uncertainties:**
- Hepatic function assessments (AST, ALT not provided)
- Coagulation laboratory assessments (PT, PTT not provided)
- Life expectancy as evaluated by the Investigator

**Assessment:**
> The patient's cancer type and treatment history align with the trial's focus on NSCLC, particularly with the KRAS G12C mutation. The patient has refractory disease, meets the ECOG criterion, and has no brain metastases, all indicating strong eligibility despite minor uncertainties regarding organ function and life expectancy assessments.

---

### [NCT06607185](https://clinicaltrials.gov/study/NCT06607185)

**A Phase 1a/1b Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors**

- **Sponsor**: Eli Lilly and Company
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Cancer type is NSCLC which is studied in the trial.
- Has KRAS G12C mutation confirmed by NGS.
- ECOG performance status is 1.
- Currently has measurable disease with progressive hepatic metastases.

**Assessment:**
> The patient's cancer type matches the trial indication (NSCLC). The patient has prior therapy, but the trial is designed for previously treated patients. Additionally, the patient meets other requirements including biomarker presence and ECOG status.

---

### [NCT06720987](https://clinicaltrials.gov/study/NCT06720987)

**A Phase 1/1b, Open-label, Multicenter, Dose Escalation and Dose Optimization Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of KQB365 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies With KRAS G12S or G12C Mutations**

- **Sponsor**: Kumquat Biosciences Inc.
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has NSCLC which is a solid tumor malignancy.
- Patient has KRAS G12C mutation.
- Patient has unresectable or metastatic disease.
- Patient has adequate organ function as indicated by normal LFTs and creatinine.
- Patient meets ECOG status requirement (ECOG 1).
- Patient has no brain metastases.

**Assessment:**
> The patient has NSCLC, which is a solid tumor malignancy, and carries the required KRAS G12C mutation, aligning with the trial's focus. The patient has undergone prior treatments but does not require treatment-naive status, as the trial includes previously treated patients. All other criteria have been met.

---

### [NCT06917079](https://clinicaltrials.gov/study/NCT06917079)

**A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-11818 in Subjects With Advanced KRAS Mutant Cancers**

- **Sponsor**: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has Stage IV non-small cell lung cancer (adenocarcinoma)
- Patient has KRAS G12C mutation confirmed by NGS
- Patient has ECOG status of 1

**Assessment:**
> The patient's cancer type (NSCLC) matches the trial indication for KRAS mutant cancers. The patient has the required biomarker (KRAS G12C), meets the ECOG performance status criteria, and does not have untreated brain metastases. Additionally, the patient is previously treated, which aligns with the trial's patient population.

---

### [NCT07094204](https://clinicaltrials.gov/study/NCT07094204)

**A Phase 1 Study of ASP5834 in Participants With Locally Advanced (Unresectable) or Metastatic Solid Tumor Malignancies With KRAS Mutations or KRAS Amplifications**

- **Sponsor**: Astellas Pharma Inc
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Histologically confirmed metastatic NSCLC
- Documented KRAS G12C mutation
- ECOG status of 1
- Received prior standard therapy with platinum-based chemotherapy and checkpoint inhibitor therapy

**? Uncertainties:**
- Verification of adequate organ function based on lab values

**Assessment:**
> The patient's cancer type (NSCLC) matches the trial's indication for KRAS-mutated non-small cell lung cancer, and the patient has prior treatments consistent with eligibility. All primary criteria appear to be met, but clarification on lab values for organ function is needed.

---

### [NCT06265285](https://clinicaltrials.gov/study/NCT06265285)

**Pilot Single-Arm, Pragmatic Trial of In-Home Versus In-Clinic Subcutaneous Nivolumab Administration Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program**

- **Sponsor**: Mayo Clinic
- **Phase**: Phase 2
- **Status**: Recruiting
- **Confidence**: 80%

**âœ“ Supporting Factors:**
- Cancer type: NSCLC matches the conditions studied
- ECOG status: 1
- Prior therapies: Patient has progressed on platinum-based chemotherapy
- Age: 65 (â‰¥ 18 years)
- Absolute neutrophil count (ANC): 3.2 (â‰¥ 1500/Î¼L)
- Platelet count: 245k (â‰¥ 100,000/Î¼L)
- Creatinine: 1.1 (â‰¤ 2.0 x ULN is acceptable)
- No history of autoimmune disease
- No brain metastases

**? Uncertainties:**
- Serum total bilirubin and AST/ALT levels not provided to confirm liver function
- Residence within 35 miles of the clinic not confirmed, but the patient is in the United States
- Wi-Fi connectivity status not provided

**Assessment:**
> The patient's cancer type (NSCLC) matches the trial conditions, and he is in a treatment line appropriate for the trial. Supporting factors confirm he meets key eligibility criteria, though there are minor uncertainties primarily regarding organ function and geographical requirements.

---

### [NCT04613596](https://clinicaltrials.gov/study/NCT04613596)

**A Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation**

- **Sponsor**: Mirati Therapeutics Inc.
- **Phase**: Phase 2/Phase 3
- **Status**: Recruiting
- **Confidence**: 70%

**âœ“ Supporting Factors:**
- Histologically confirmed diagnosis of metastatic NSCLC with KRAS G12C mutation
- Patient has PD-L1 TPS of 40%
- No evidence of brain metastases

**âœ— Potential Conflicts:**
- Patient's PD-L1 TPS is 40%, which does not meet the Phase 3 requirement of TPS >= 50%

**Assessment:**
> The patient has a confirmed diagnosis of metastatic NSCLC and has a KRAS G12C mutation which aligns with the trial's inclusion criteria. However, the PD-L1 TPS of 40% does not meet the Phase 3 requirement of >= 50%, leading to some qualification concerns.

---

### [NCT06249282](https://clinicaltrials.gov/study/NCT06249282)

**A Phase I Clinical Trial of Carfilzomib in Combination With Sotorasib in Patients With KRASG12C Mutated Advanced Non-Small Cell Lung Cancer**

- **Sponsor**: City of Hope Medical Center
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 10%

**âœ“ Supporting Factors:**
- Patient has Stage IV non-small cell lung cancer (NSCLC).
- Patient has a confirmed KRAS G12C mutation.
- Patient's ECOG status is 1.
- Patient does not have any brain metastases.
- Patient's ANC is 3.2, which meets the criterion of ANC â‰¥ 1,500/mm^3.
- Patient's platelets are 245k, which meets the criterion of platelets â‰¥ 100,000/mm^3.

**âœ— Potential Conflicts:**
- Patient has had prior therapies including a KRAS inhibitor (pembrolizumab), but the trial requires patients who have failed prior KRAS inhibitors.

**? Uncertainties:**
- Complete details on liver function tests (LFTs) and creatinine levels are not provided; however, they are stated to be normal and creatinine is 1.1.

**Assessment:**
> The patient has the correct cancer type and KRAS mutation but is excluded due to prior therapies that do not align with trial requirements for previous treatment with KRAS inhibitors.

---

## ðŸŸ¡ MEDIUM Likelihood (3 trials)

### [NCT05074810](https://clinicaltrials.gov/study/NCT05074810)

**A Phase 1/2 Study of Avutometinib (VS-6766) in Combination With Sotorasib With or Without Defactinib in Patients With KRAS G12C Mutant Non-Small Cell Lung Cancer (NSCLC)**

- **Sponsor**: Verastem, Inc.
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 65%

**âœ“ Supporting Factors:**
- Age: 65
- Sex: male
- Cancer type: NSCLC
- Biomarkers: KRAS G12C
- ECOG status: 1
- Prior therapies: carboplatin/pemetrexed, pembrolizumab (received appropriate treatment with at least one prior systemic regimen)
- No brain metastases
- Adequate organ function (Creatinine 1.1, LFTs normal, ANC 3.2, platelets 245k)

**âœ— Potential Conflicts:**
- Patient has received prior therapies and the trial includes patients who have not been previously treated with a KRAS inhibitor to be included in Part B.

**Assessment:**
> The patient's cancer type of NSCLC with KRAS G12C mutation matches the trial's subject. However, due to prior treatments with a G12C inhibitor (pembrolizumab), there is uncertainty regarding the treatment line eligibility as the trial specifies exposure to G12C inhibitors for inclusion criteria. Thus, the patient likely qualifies but requires further verification regarding the treatment line.

---

### [NCT05609578](https://clinicaltrials.gov/study/NCT05609578)

**A Phase 2 Trial of Combination Therapies With Adagrasib in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation**

- **Sponsor**: Mirati Therapeutics Inc.
- **Phase**: Phase 2
- **Status**: Recruiting
- **Confidence**: 65%

**âœ“ Supporting Factors:**
- Patient has a diagnosis of advanced NSCLC with KRAS G12C mutation.
- Patient has PD-L1 TPS of 40%.
- Patient presents no brain metastases.

**âœ— Potential Conflicts:**
- Patient has previously received systemic therapy (carboplatin/pemetrexed, pembrolizumab) which may impact eligibility.

**? Uncertainties:**
- Organ function lab results are clear, but history of treatments used and their timelines for the specific cohort may need more clarity.

**Assessment:**
> The disease type is a match, but the patient has received prior systemic therapies, making it unclear if they are eligible for the trial which seems focused on treatment-naive or first-line patients. Additionally, the PD-L1 TPS is below 50%, qualifying for a specific cohort, but prior treatment history complicates eligibility further.

---

### [NCT06545331](https://clinicaltrials.gov/study/NCT06545331)

**A Dose-Escalation and Expansion Study of XB010 as a Single Agent and Combination Therapy in Subjects With Locally Advanced or Metastatic Solid Tumors**

- **Sponsor**: Exelixis
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 65%

**âœ“ Supporting Factors:**
- Age: 65
- ECOG status: 1
- Cancer type: NSCLC
- Biomarkers: KRAS G12C

**âœ— Potential Conflicts:**
- Prior therapies: The patient has received prior systemic therapy (carboplatin/pemetrexed, pembrolizumab) which may not align with trial objectives aimed at treatment-naive patients.

**? Uncertainties:**
- Specific criteria for biomarker qualification regarding acceptable levels of PD-L1 expression are not provided.

**Assessment:**
> The patient's cancer type (NSCLC) matches the trial conditions, and the ECOG status and age are acceptable. However, the patient has received prior systemic therapies, potentially conflicting with the treatment line criteria if the trial is aimed at treatment-naive patients. This uncertainty affects the overall confidence level.

---

## ðŸŸ  LOW Likelihood (1 trials)

### [NCT06130254](https://clinicaltrials.gov/study/NCT06130254)

**Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers**

- **Sponsor**: M.D. Anderson Cancer Center
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 20%

**âœ“ Supporting Factors:**
- Patient has NSCLC with KRAS G12C mutation.
- Patient has progressive disease after prior therapies.
- ECOG status 1.

**âœ— Potential Conflicts:**
- Trial requires KEAP1 co-mutation for NSCLC eligibility, which the patient does not have.

**? Uncertainties:**
- Laboratory values within the screening period: unspecified hemoglobin levels.

**Assessment:**
> The patient's cancer type of NSCLC aligns with the trial. However, the trial requires both KRAS G12C and KEAP1 co-mutations for NSCLC eligibility, which the patient does not possess, leading to exclusion.

---

## Excluded (70 trials)

### Excluded by Fast Filter

| NCT ID | Reason |
|--------|--------|
| [NCT04130516](https://clinicaltrials.gov/study/NCT04130516) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT04300556](https://clinicaltrials.gov/study/NCT04300556) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT04589845](https://clinicaltrials.gov/study/NCT04589845) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05419375](https://clinicaltrials.gov/study/NCT05419375) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05638295](https://clinicaltrials.gov/study/NCT05638295) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05892068](https://clinicaltrials.gov/study/NCT05892068) | Trial requires female patients |
| [NCT06401330](https://clinicaltrials.gov/study/NCT06401330) | Patient age 65 is above maximum age 30 |
| [NCT00033137](https://clinicaltrials.gov/study/NCT00033137) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT04551378](https://clinicaltrials.gov/study/NCT04551378) | Patient age 65 is above maximum age 39 |
| [NCT04929223](https://clinicaltrials.gov/study/NCT04929223) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05720117](https://clinicaltrials.gov/study/NCT05720117) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05876923](https://clinicaltrials.gov/study/NCT05876923) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT06555744](https://clinicaltrials.gov/study/NCT06555744) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT06804824](https://clinicaltrials.gov/study/NCT06804824) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT06807619](https://clinicaltrials.gov/study/NCT06807619) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |

### Excluded by Eligibility Assessment

| NCT ID | Sponsor | Reason |
|--------|---------|--------|
| [NCT06875310](https://clinicaltrials.gov/study/NCT06875310) | Mirati Therapeutics  | Patient has received prior systemic therapy (carboplatin/pemetrexed and pembrolizumab) which conflicts with trial's requirement for treatment-naive patients |
| [NCT04585477](https://clinicaltrials.gov/study/NCT04585477) | Stanford University | Patient has Stage IV NSCLC, while trial includes only Stage I to III NSCLC. |
| [NCT05261399](https://clinicaltrials.gov/study/NCT05261399) | AstraZeneca | Patient has NSCLC with KRAS G12C mutation; trial requires EGFR mutation (exon19 deletion, L858R mutation, and/or T790M). |
| [NCT05578326](https://clinicaltrials.gov/study/NCT05578326) | UNC Lineberger Compr | Patient has non-small cell lung cancer (NSCLC), but trial is for small cell lung cancer (SCLC). |
| [NCT05500092](https://clinicaltrials.gov/study/NCT05500092) | Montefiore Medical C | Patient has previously treated NSCLC (carboplatin/pemetrexed and pembrolizumab), while trial requires treatment-naive patients. |
| [NCT06248606](https://clinicaltrials.gov/study/NCT06248606) | Ryan Gentzler, MD | Patient has no untreated brain metastases, which is a requirement for the trial |
| [NCT06312137](https://clinicaltrials.gov/study/NCT06312137) | Merck Sharp & Dohme  | Patient has Stage IV NSCLC which does not align with the trial's requirement for resectable Stage II to IIIB NSCLC. |
| [NCT06561386](https://clinicaltrials.gov/study/NCT06561386) | Bristol-Myers Squibb | Patient has prior systemic anti-cancer therapy (carboplatin/pemetrexed and pembrolizumab), but trial requires treatment-naive participants. |
| [NCT06593522](https://clinicaltrials.gov/study/NCT06593522) | Amgen | Patient has KRAS G12C mutation, which is excluded by the trial criteria that state tumors harboring KRAS G12C are not eligible. |
| [NCT06582771](https://clinicaltrials.gov/study/NCT06582771) | Memorial Sloan Kette | Patient has received prior therapies in the advanced setting (carboplatin/pemetrexed and pembrolizumab), while the trial requires no prior therapy in the advanced setting. |
| [NCT06793215](https://clinicaltrials.gov/study/NCT06793215) | Hoffmann-La Roche | Patient has received prior systemic treatment (carboplatin/pemetrexed + pembrolizumab), whereas the trial requires treatment-naive patients. |
| [NCT06890598](https://clinicaltrials.gov/study/NCT06890598) | Eli Lilly and Compan | Patient has progressive disease after prior therapies, which does not meet the inclusion criteria for Part B which specifies 'without progression on concurrent platinum-based chemoradiotherapy'. |
| [NCT02596490](https://clinicaltrials.gov/study/NCT02596490) | M.D. Anderson Cancer | Currently receiving treatment at MD Anderson Cancer Center is not confirmed in the patient profile. |
| [NCT03774758](https://clinicaltrials.gov/study/NCT03774758) | University of Califo | Patient has non-small cell lung cancer (NSCLC) but the trial focuses on patients undergoing lung cancer screening, which is not a treatment study. |
| [NCT05332925](https://clinicaltrials.gov/study/NCT05332925) | Jun Zhang, MD, PhD | Patient is not treatment-naive (previous treatment with pembrolizumab). |
| [NCT05254184](https://clinicaltrials.gov/study/NCT05254184) | Sidney Kimmel Compre | Patient has received prior systemic therapy (carboplatin/pemetrexed and pembrolizumab) for Stage IV NSCLC which does not meet the trial's requirement for treatment-naive patients. |
| [NCT06225804](https://clinicaltrials.gov/study/NCT06225804) | Abbisko Therapeutics | Patient is not treatment-naive; has received prior systemic therapies, but the trial requires treatment-naive or previously treated patients. |
| [NCT06712745](https://clinicaltrials.gov/study/NCT06712745) | University of Texas  | Patient has prior systemic therapy (carboplatin/pemetrexed, pembrolizumab) which conflicts with potential eligibility for treatment-naive patients. |
| [NCT06671613](https://clinicaltrials.gov/study/NCT06671613) | VA Office of Researc | Patient has prior therapy with pembrolizumab, while the trial requires patients to be treatment-naive or only on PD (L)1 inhibitor alone with 50% PD-L1 expression. |
| [NCT04956640](https://clinicaltrials.gov/study/NCT04956640) | Eli Lilly and Compan | Patient has prior systemic therapy (carboplatin/pemetrexed and pembrolizumab) while the trial specifies treatment-naive/first-line patients. |
| ... | ... | *and 35 more* |

## Search Terms Used

| Term | Source | Confidence |
|------|--------|------------|
| KRAS G12C | manual | 1.0 |
| KRASG12C | manual | 0.9 |
| KRAS-G12C | manual | 0.9 |
| NSCLC | manual | 1.0 |
| KRAS G12C NSCLC | manual | 1.0 |
| KRAS G12C non-small cell lung cancer | llm | 0.9 |
| NSCLC KRAS G12C | llm | 0.9 |
| non-small cell lung cancer | llm | 0.8 |
| lung adenocarcinoma | llm | 0.8 |
| KRAS p.G12C | llm | 0.9 |
| KRASp.G12C | llm | 0.8 |
| KRAS-p.G12C | llm | 0.8 |

## Information That Would Improve Matches

The following patient data was not provided but would help refine eligibility assessment:

- **Organ function labs** (hematology, liver, renal) - required by all interventional trials
- **Measurable disease status** (per RECIST 1.1) - required for most therapeutic trials
- **Life expectancy estimate** - many trials require â‰¥3 months
